Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Transcenta Returns Select Lilly Assets in Portfolio Restructuring, Retains Blosozumab Rights

Fineline Cube Jul 8, 2026
Company Deals Digital

Hanx Biopharmaceuticals Partners with HUST-CityU Macau Institute to Establish AI-Driven Drug Discovery Joint Laboratory

Fineline Cube Jul 8, 2026
Company Deals

Nanjing Pharmaceutical Acquires Majority Stakes in Datsing Bio-Tech and Kejian Technology for RMB 750 Million

Fineline Cube Jul 8, 2026
Company Deals

MindRank Secures $52 Million Series B to Advance AI Drug Discovery Platform and Phase III GLP-1RA Candidate MDR-001

Fineline Cube Jul 8, 2026
Company Deals

Sino Biopharmaceutical Expands GSK Partnership to Commercialize Trelegy and Anoro Ellipta in China

Fineline Cube Jul 8, 2026
Policy / Regulatory

China Adds Methoxyethyl Etomidate, Loretomidate and Solriamfetol to Controlled Psychotropic Substances List

Fineline Cube Jul 8, 2026
Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors

Fineline Cube Jul 8, 2026
Company Drug

Qihan Biotech Secures NMPA Approval for Dual-Target Allogeneic CAR-T Therapy QT-019C in Refractory Lupus

Fineline Cube Jul 8, 2026
Policy / Regulatory

China’s Pharma Distribution Market Grows Steadily in 2022, Driven by Retail Sales Surge

Fineline Cube Nov 29, 2023

The Ministry of Commerce (MofCOM) has released its annual statistical review of China’s pharmaceutical distribution...

Company Deals

BMS and Avidity Biosciences Join Forces on $2.2 Billion Cardiology Antibody Oligonucleotide Conjugate Deal

Fineline Cube Nov 29, 2023

Bristol Myers Squibb (BMS, NYSE: BMY) has announced a strategic partnership with Avidity Biosciences (NASDAQ:...

Company Deals

Blue Sail Medical and China National Medical Device Forge Strategic Partnership for Growth

Fineline Cube Nov 29, 2023

Blue Sail Medical Co., Ltd (SHE: 002382), a prominent player in China’s medical device sector,...

Company

Alibaba Health Reports 12.7% Revenue Growth in H1 2023, Driven by Pharmaceutical and Digital Services

Fineline Cube Nov 29, 2023

Alibaba Health Information Technology Ltd (HKG: 0241), based in China, has released its financial results...

Company Drug

JW Therapeutics Secures Priority Review for Carteyva in Relapsed/Refractory Mantle Cell Lymphoma

Fineline Cube Nov 29, 2023

JW Therapeutics (HKG: 2126), based in China, has announced that its CAR-T cell therapy, Carteyva...

Company Drug

Beijing Konruns Pharmaceutical Launches Phase III Study for KC1036 in Advanced Esophageal Cancer

Fineline Cube Nov 29, 2023

Beijing Konruns Pharmaceutical Co., Ltd (SHA: 603590), based in Beijing, has received approval from China’s...

Company Drug

Lee’s Pharmaceutical Secures NMPA Approval for Adasuve, Pioneering Loxapine Inhaler for Agitation

Fineline Cube Nov 29, 2023

Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) has secured marketing approval from China’s National Medical Products...

Company Medical Device

AK Medical Holdings Receives NMPA Approval for Hip Surgery Navigation System iBot

Fineline Cube Nov 29, 2023

AK Medical Holdings Ltd (HKG: 1789), a Chinese medical technology company, has announced that it...

Company Drug

Gracell Biotechnologies Gets FDA Green Light for FasTCAR-T Therapy in Systemic Lupus Erythematosus

Fineline Cube Nov 29, 2023

Gracell Biotechnologies Inc., a Suzhou-based biotech company (NASDAQ: GRCL), has received approval from the US...

Company Deals

Mabwell Bioscience Enters Thai Market with Licensing Deal with Innobic

Fineline Cube Nov 29, 2023

Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062), a Chinese biopharmaceutical company, has announced the signing...

Company Deals

Taihe Weiye Biotechnology Secures RMB 300 Million in Series A+ Financing to Expand Production

Fineline Cube Nov 29, 2023

Chengdu Taihe Weiye Biotechnology Co., Ltd, a Chinese developer of protected amino acids drugs, has...

Company Drug

Dupixent Trial Success Reinforces Potential in Moderate-to-Severe COPD Treatment

Fineline Cube Nov 28, 2023

Regeneron Pharmaceuticals (NASDAQ: REGN) and Sanofi (NASDAQ: SNY) have announced that a late-stage replicate trial...

Company Drug

AbbVie’s Epcoritamab Earns EMA Review and FDA Breakthrough Designation for Follicular Lymphoma

Fineline Cube Nov 28, 2023

AbbVie’s (NYSE: ABBV) bispecific antibody (BsAb) Tepkinly/Epkinly (epcoritamab) has been accepted for review by the...

Company R&D

AstraZeneca to Open R&D Center in Hong Kong, Focusing on Cell and Gene Therapies

Fineline Cube Nov 28, 2023

UK pharmaceutical giant AstraZeneca (AZ; NASDAQ: AZN) has concluded a roughly 12-month discussion period with...

Company

Bayer Faces Backlash After Bond Sale Preceding Late-Stage Pipeline Failure

Fineline Cube Nov 28, 2023

German pharmaceutical giant Bayer (ETR: BAYN) is facing investor and analyst scrutiny following its issuance...

Company Drug

Everest Medicines’ Nefecon for IgAN Receives NMPA Approval in China

Fineline Cube Nov 28, 2023

Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced that its New Drug Application...

Company Deals

Beijing QL Biopharmaceutical Boosts Pipeline with RMB 200 Million Series B+ Round

Fineline Cube Nov 28, 2023

Beijing QL Biopharmaceutical Co., Ltd., a Chinese biopharmaceutical company, has reportedly secured nearly RMB 200...

Company Drug

Henlius Biotech Gets FDA Clearance for Clinical Study of PD-L1 Targeting ADC HLX43

Fineline Cube Nov 28, 2023

Shanghai Henlius Biotech Inc. (HKG: 2696), a Chinese biopharmaceutical company, has received approval from the...

Company Drug

CSPC Pharmaceutical Gets NMPA Green Light for SYH2038 Solid Tumor Study

Fineline Cube Nov 28, 2023

CSPC Pharmaceutical Group Ltd (HKG: 1093), a Chinese pharmaceutical company, has announced that it has...

Company Drug

Abbisko Therapeutics Launches Phase II Trial for Pimocitinib in Advanced Pancreatic Cancer

Fineline Cube Nov 28, 2023

Abbisko Therapeutics Co., Ltd (HKG: 2256), a Shanghai-based biotechnology company, has announced the initiation of...

Posts pagination

1 … 463 464 465 … 692

Recent updates

  • Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors
  • AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy
  • OTR Therapeutics Partners with LG Chem to Accelerate Early-Stage Oncology Programs with China-Global Development Model
  • Qihan Biotech Secures NMPA Approval for Dual-Target Allogeneic CAR-T Therapy QT-019C in Refractory Lupus
  • Insilico Medicine Launches Phase 3 Trial for AI-Discovered Rentosertib in Idiopathic Pulmonary Fibrosis
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Hengrui Pharmaceuticals Secures NMPA Clinical Approval for First-in-Class SHR-4685 in Advanced Solid Tumors

Others

AstraZeneca and Ionis Launch Wainua (Eplontersen) in China for Hereditary ATTR Amyloidosis with Polyneuropathy

Others

OTR Therapeutics Partners with LG Chem to Accelerate Early-Stage Oncology Programs with China-Global Development Model

Company Drug

Qihan Biotech Secures NMPA Approval for Dual-Target Allogeneic CAR-T Therapy QT-019C in Refractory Lupus

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.